相关实验视频

Updated: May 5, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

晚期胆道癌的二线胺基化疗:基于随机试验的个体患者级数据的元分析

Jaewon Hyung¹, Minsu Kang², Ilhwan Kim³

¹Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Cancer research and treatment

|October 22, 2024

概括

与修改后的FOLFOX或修改后的FOLFIRI相比,在晚期的胆道癌症中,脂质组的义诺他干加上甲酸/莱科沃林显示出更高的整体存活率. 在选择治疗方案时,安全概况也需要考虑.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
临床试验临床试验

背景情况:

晚期胆道癌 (BTC) 缺乏对推的二线胺基化学疗法的对比.
确定最佳的二线治疗对于改善BTC患者的治疗结果至关重要.

研究的目的:

为了比较脂质体里诺特干 (nal-IRI) 加上5-FU/LV对抗mFOLFOX,mFOLFIRI和5-FU/LV在高级BTC中的疗效.
评估BTC的不同二线化疗方案的整体存活率 (OS) 和安全概况.

主要方法:

两个第二阶段试验 (NIFTY和FIReFOX) 的个体患者水平元分析.
纳尔-IRI + 5-FU/LV,5-FU/LV,mFOLFOX和mFOLFIRI的比较使用日志等级测试和Cox比例危险建模.
分析包括277名来自治疗意向人群的患者.

主要成果:

与mFOLFOX (p=0.02) 和mFOLFIRI (p=0.03) 相比,Nal-IRI + 5-FU/LV显示出明显更好的生存状况.
多变量分析表明一致的趋势有利于nal-IRI + 5-FU/LV,尽管在统计学上并不显著 (HRs 1.39和1.36).
在mFOLFOX,mFOLFIRI和5-FU/LV之间没有观察到显著的OS差异. 腹在纳尔-IRI + 5-FU/LV时更频繁;外围神经病变在mFOLFOX时更频繁.

结论:

与mFOLFOX和mFOLFIRI相比,在晚期BTC中,脂质体里诺特干加上5-FU/LV显示出更高的生存结果.
选择二线治疗方案应平衡有效性与不同的安全性,包括腹和神经病变.

关键词:

胆道瘤是什么意思胆道瘤光皮里米丁 (Fluoropyrimidine) 是一种酸的化合物.脂质体内氨基酸氨基酸.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...